WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsMiniMed Group, Inc. Common Stock (MMED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 839% more annual revenue ($29.14B vs $3.10B). MDLN leads profitability with a 3.3% profit margin vs -10.7%. MDLN earns a higher WallStSmart Score of 52/100 (C-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.5Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.79

MMED

Avoid

35

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.0Quality: 6.3
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN3 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Market CapQuality
$65.23B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

MMED3 strengths · Avg: 9.3/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
15.6%8/10

15.6% revenue growth

Areas to Watch

MDLN4 concerns · Avg: 3.5/10
P/E RatioValuation
32.1x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.794/10

Distress zone — elevated risk

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Debt/EquityHealth
1.123/10

Elevated debt levels

MMED4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Profit MarginProfitability
-10.7%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Market Cap, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bull Case : MMED

The strongest argument for MMED centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Piotroski F-Score.

Key Dynamics to Monitor

MDLN profiles as a value stock while MMED is a growth play — different risk/reward profiles.

MMED is growing revenue faster at 15.6% — sustainability is the question.

MDLN generates stronger free cash flow (316M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 35/100) and 10.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

MiniMed Group, Inc. Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Want to dig deeper into these stocks?